In a Phase II study reported in 2024 involving 168 patients with NASH, moderate to advanced fibrosis (F2F3), and NAS 4, a significantly greater proportion of patients in the denifanstat group achieved the primary endpoint compared with placebo, with statistically meaningful improvements in fibrosis as well
Each patient on semaglutide or lixisenatide was matched with two patients who also had diabetes but were not taking the drugs, who shared similar characteristics such as age, gender and health conditions
Although the great majority of published studies evaluate the use of injectable active substances in body fat, their application on the face also brings excellent results with minimal side effects
According to the Ozempic prescribing information, this dose is not intended for effective glycemic control or significant weight loss
Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs
